The University of Chicago Header Logo

Connection

Hedy Kindler to Receptor, trkA

Back to Details
This is a "connection" page, showing publications Hedy Kindler has written about Receptor, trkA.
Hedy Kindler
Connection Strength
0.063
Receptor, trkA
  1. Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs. 2005 Jan; 23(1):31-7.
    View in: PubMed
    Score: 0.063
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.